Eric Lefkofsky, the CEO and co-founder of Tempus, is revolutionizing cancer treatments through his tech venture. Under his leadership, Tempus is developing the largest online library in the world that contains both clinical and molecular data of cancer patients. The firm also developed an operating system and making the data available to physicians around the world. Tempus works on a mechanism that uses transcriptomic and genomic sequencing clubbed with the advancement of machine learning to help the physicians to understand the nature of the tumor of a patient better. It should also be noted that the clinical and molecular data are useful for doctors to offer personalized treatment options and read full article.
The firm also provides reporting services that include a detailed report about the patient with highlighted and actionable items included its results for helping the physicians to take decisions on treatment plans. Finally, Tempus also offers validation services that include collaborating with researchers and develop cell-culture technology and automation for enabling screening options for therapies that are administered on animal and synthetic models. The technology solutions that target cancer treatment has become highly popular in the recent years considering it was the first major attempt to map the genome sequencing of cancer patients to drive better results in treatments and learn more about Eric.
Eric Lefkofsky has made the firm collaborating with various research institutes around the world in various aspects of cancer treatment. In the last week of August, Tempus made a partnership with Davis Comprehensive Cancer Center – University of California, to conduct research in precision medicine for advancing in Next Generation Sequencing and clinical care. Lefkofsky is also involved in many philanthropic activities that are focusing community support services. He founded Lefkofsky Family Foundation in 2016 along with his wife Liz, and it offers high-impact programs, research, and initiatives to improve the quality of human life. Its focus areas include education, human rights, medical research, and cultural initiatives.
Lefkofsky is also the co-founder of a number of firms including Echo Global Logistics, Groupon, InnerWorkings, Uptake, Mediaocean, and Lightbank. He completed his graduation from the University of Michigan and earned his J.D. from the University of Michigan, before starting his business ventures.
Oncotarget is a weekly scientific journey that focuses on oncology, which is the study of prevention, analysis and treatment of cancer. The journal is freely published online and is accessible to all. Since its launch in 2010, Oncotarget has been instrumental in extensive research and analysis of different types of cancers and given suggestions on the best treatment options. It scrutinizes new and prevailing cancer therapies and confirms if they are applied in a manner that is acceptable to both the patients and the healthcare providers. Here are a few highlights of the journal:
All research information submitted to Oncotarget is verified by a panel of experts before it is published. All necessary modifications are made to ensure that the information published is correct and has been written in a way that readers can easily understand. The panel comprises qualified professionals, so readers are confident that the content of the journal is authentic and meets the required standards. Additionally, Oncotarget subscribes to the standards of the Committee on Publication Ethics, and this boosts the readers’ confidence in the journal.
Oncotarget is available online, so one can access it on any electronic device such as a computer or a smart phone. If one finds it useful, they can print a copy or share it with their peers. This free accessibility has helped many people gain valuable information at their convenience. Readers can also save the portions they find useful and read later at their comfort.
Due to the continuous extensive research, Oncotarget contains the most current information on the best treatment options for cancer patients. It advises on the alternative therapies to medications that are pain-free and affordable such as living a healthy lifestyle.
Oncotarget has created a platform for many scientists and researchers to publish their work and create awareness on cancer globally. Since the journal is electronic, there are no space limitations thus can hold many articles. Oncotarget has proven to be a crucial tool in creating feasible solutions to cancer patients worldwide.
To know more click here
Eric Lefkofsky is an American entrepreneur who is most known for being the chairman and co-founder of the very popular e-commerce website Groupon. He was born in Michigan in 1969 and has been involved in many different business and philanthropic endeavors ever since. Continue reading to find out more about Eric Lefkofsky’s educational background as well as his philanthropic endeavors.
Eric Lefkofsky graduated high school in 1987. He attended the Southfield-Lathrup High School located in Lathrup Village, Michigan. It is one of the oldest high schools in the Southfield area. They are known for their extensive and well supported music program. They are also known locally for their amazing basketball team which earned a state title.
After graduating high school Lefkofsky attended the University of Michigan located in Ann Arbor, Michigan. It is known as one of the top schools. He eventually graduated with honors in 1991.
After graduating from the University of Michigan in 1991 Eric Lefkofsky then went on to continue his education at the University of Michigan Law School also located in Ann Arbor, Michigan. Lefkofsky ended up receiving his Juris doctor degree in 1993 and more information click here.
Throughout his busy career Eric Lefkofsky has also been involved in many different philanthropic endeavors. In 2013 he and his wife joined The Giving Pledge which is a big charitable organization run by Bill Gates and Warren Buffett. The idea of the pledge is that wealthy individuals will donate much of their money to different charities throughout their life and death. To date The Giving Pledge has pledged to donate over 700 billion dollars to worthy causes.
Eric Lefkofsky and his wife Elizabeth also started their own charitable trust back in 2006 named the Lefkofsky foundation. It works to support a variety of different charitable organizations. They work to enhance the well-being of women and men all over the world. To date they have helped fund more than 50 different charitable organizations.
These are just a few of the many different philanthropic endeavors that Eric Lefkofsky has been a part of. He continues to work every day to make the world a better place for people to live.
More visit: https://twitter.com/lefkofsky
Many people’s lives have been touched by cancer in a variety of ways in the world today. Chances are, if you aren’t afflicted with the disease yourself that you may know someone who is. Cancer is one of the great killers of this era. Therefore, there has been much funding contributed to companies who research various therapies for treating the devastating disease. Seattle Genetics is one of these companies.
Seattle Genetics is a biotechnology company based in a suburb of Seattle that specializes in developing antibody-based therapies for the treatment of cancer. The company’s drive to commercialize its revolutionary cancer treatment therapies has led to them becoming the industry leader in antibody-drug conjugates (ADCs).
Since its founding in 1998 by Clay Siegall, Seattle Genetics has underwent numerous financing rounds. Last year the company underwent its largest ever by a wide margin. During its historic financing round, Seattle Genetics took its then $480 million public stock offering and increased it by more than $70 by way of its over-allotment option.
According to Seattle Genetics CEO Clay Siegall, the amount of interest the company received from serious investors played a huge role in the company’s ability to increase its offering. Siegall also claimed the company planned to do more with the proceeds of its offering than just expanding the company. It also planned to use the proceeds to help further develop its drug pipeline, which in turn would help grow the application of its flagship cancer drug Adcetris.
All of the expansion and growth the company went through in 2015 had it busting at the seams. To make room for the growth Seattle Genetics began looking to startup other office locations besides its headquarters in Bothell, Washington, though the company planned to keep to stay in the suburban region and lease a place in Canyon Park area in Bothell. By 2020, the company expects to have an employee headcount of 1,300.
About Clay Siegall
Clay Siegall is the co-founder and current CEO of biotechnology company Seattle Genetics. The scientist built Seattle Genetics on the bases of being one of the most innovative research and drug development practices that specifically focuses on helping cancer patients with top of the line therapies. Seattle Genetics has garnered much notoriety under the leadership of Clay Siegall since its creation.